Tianyan Pharmaceutical is a limited liability company incorporated in the Cayman Islands on February 25, 2011. The company is a platform-driven biopharmaceutical company in the development stage of clinical products with independent platform output. The company is committed to discovering and developing new cancer immunotherapies based on original antibodies. With a powerful platform that combines computational biology and artificial intelligence, the company has developed new antibodies with high safety and efficacy, bringing good news to more cancer patients. The company's antibody discovery engine, the "Dynamic Precision Library" (Dynamic Precision Library), is driving the development of Tianyan Pharmaceutical's product pipeline, dedicated to creating potential global innovations or best-in-class products. The company has established strategic partnerships with a number of well-known global companies. These partners take full advantage of the company's cutting-edge technologies, such as safer precision targeted antibody-drug conjugate (ADC) and innovative antibody designs. Under the leadership of a world-class core team in the field of precision antibody engineering research and development, the company is committed to providing new solutions to long-standing therapeutic challenges.